Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Other Operating Expenses (2016 - 2025)

United Therapeutics (UTHR) has disclosed Other Operating Expenses for 17 consecutive years, with $103.4 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 36.23% to $103.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $384.4 million through Dec 2025, up 24.12% year-over-year, with the annual reading at $384.4 million for FY2025, 24.12% up from the prior year.
  • Other Operating Expenses hit $103.4 million in Q4 2025 for United Therapeutics, up from $100.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $140.2 million in Q1 2021 to a low of $25.9 million in Q1 2022.
  • Historically, Other Operating Expenses has averaged $67.1 million across 5 years, with a median of $70.6 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: plummeted 82.12% in 2021 and later soared 115.82% in 2023.
  • Year by year, Other Operating Expenses stood at $34.6 million in 2021, then surged by 69.94% to $58.8 million in 2022, then increased by 20.75% to $71.0 million in 2023, then grew by 6.9% to $75.9 million in 2024, then skyrocketed by 36.23% to $103.4 million in 2025.
  • Business Quant data shows Other Operating Expenses for UTHR at $103.4 million in Q4 2025, $100.9 million in Q3 2025, and $87.6 million in Q2 2025.